This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Skoulidis F , Li BT , Dy GK , Price TJ , Falchook GS , Wolf J , Italiano A , Schuler M , Borghaei H , Barlesi F , Kato T , Curioni-Fontecedro A , Sacher A , Spira A , Ramalingam SS , Takahashi T , Besse B , Anderson A , Ang A , Tran Q , Mather O , Henary H , Ngarmchamnanrith G , Friberg G , Velcheti V , Govindan R
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
N Engl J Med. 2021 Jun 24;384(25) :2371-2381
PMID: 34096690 URL: https://www.ncbi.nlm.nih.gov/pubmed/34096690
AbstractBACKGROUND: Sotorasib showed anticancer activity in patients with KRAS p.G12C-mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of patients with non-small-cell lung cancer (NSCLC). METHODS: In a single-group, phase 2 trial, we investigated the activity of sotorasib, administered orally at a dose of 960 mg once daily, in patients with KRAS p.G12C-mutated advanced NSCLC previously treated with standard therapies. The primary end point was objective response (complete or partial response) according to independent central review. Key secondary end points included duration of response, disease control (defined as complete response, partial response, or stable disease), progression-free survival, overall survival, and safety. Exploratory biomarkers were evaluated for their association with response to sotorasib therapy. RESULTS: Among the 126 enrolled patients, the majority (81.0%) had previously received both platinum-based chemotherapy and inhibitors of programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1). According to central review, 124 patients had measurable disease at baseline and were evaluated for response. An objective response was observed in 46 patients (37.1%; 95% confidence interval [CI], 28.6 to 46.2), including in 4 (3.2%) who had a complete response and in 42 (33.9%) who had a partial response. The median duration of response was 11.1 months (95% CI, 6.9 to could not be evaluated). Disease control occurred in 100 patients (80.6%; 95% CI, 72.6 to 87.2). The median progression-free survival was 6.8 months (95% CI, 5.1 to 8.2), and the median overall survival was 12.5 months (95% CI, 10.0 to could not be evaluated). Treatment-related adverse events occurred in 88 of 126 patients (69.8%), including grade 3 events in 25 patients (19.8%) and a grade 4 event in 1 (0.8%). Responses were observed in subgroups defined according to PD-L1 expression, tumor mutational burden, and co-occurring mutations in STK11, KEAP1, or TP53. CONCLUSIONS: In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-mutated NSCLC. (Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
Notes1533-4406 Skoulidis, Ferdinandos Li, Bob T Dy, Grace K Price, Timothy J Falchook, Gerald S Wolf, Jürgen Italiano, Antoine Schuler, Martin Borghaei, Hossein Barlesi, Fabrice Kato, Terufumi Curioni-Fontecedro, Alessandra Sacher, Adrian Spira, Alexander Ramalingam, Suresh S Takahashi, Toshiaki Besse, Benjamin Anderson, Abraham Ang, Agnes Tran, Qui Mather, Omar Henary, Haby Ngarmchamnanrith, Gataree Friberg, Gregory Velcheti, Vamsidhar Govindan, Ramaswamy Orcid: 0000-0002-6964-9612 P30 CA008748/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.